Publications by authors named "S Mammoliti"
Article Synopsis
- Cemiplimab, an antibody targeting the PD-1 receptor, is being evaluated in a real-world study in Italy for patients with advanced cervical cancer who have undergone platinum-based chemotherapy, following promising initial trial results.
- The study involved 135 patients, assessing primary outcomes like progression-free survival (PFS) and overall survival (OS), along with safety and response rates to treatment.
- Results showed a median PFS of 4 months and median OS of 12 months, with anemia and fatigue being the most common side effects, highlighting the treatment's feasibility in clinical practice.
Article Synopsis
- This text appears to reference a correction made to a previously published article in the journal Frontiers in Oncology.
- The specific article is identified by its Digital Object Identifier (DOI): 10.3389/fonc.2023.1247291.
- The correction might involve updates or clarifications to the original research findings or data presented in the article.
Single-Agent Trabectedin Versus Physician's Choice Chemotherapy in Patients With Recurrent Ovarian Cancer With -Mutated and/or BRCAness Phenotype: A Randomized Phase III Trial.
J Clin Oncol
May 2024
Purpose: Literature evidence suggests that trabectedin monotherapy is effective in patients with recurrent ovarian cancer (OC) presenting mutation and/or BRCAness phenotype.
Methods: A prospective, open-label, randomized phase III MITO-23 trial evaluated the activity and safety of trabectedin 1.3 mg/m given once every 3 weeks (arm A) in mutation carriers or patients with BRCAness phenotype (ie, patients who responded to ≥two previous platinum-based treatments) with recurrent OC, primary peritoneal carcinoma, or fallopian tube cancer in comparison with physician's choice chemotherapy in the control arm (arm B; pegylated liposomal doxorubicin, topotecan, gemcitabine, once-weekly paclitaxel, or carboplatin).
Endometrial cancer (EC) is the most frequent gynecological cancer. The ESGO/ESTRO/ESP 2020 guidelines identify prognostic groups based on morpho-molecular characteristics. This study aims to evaluate the clinical applicability of NGS analysis to define an appropriate risk class and to improve the diagnostic and prognostic stratification of ECs.
View Article and Find Full Text PDFIntroduction: Endometrial cancer (EC) represents 3.4% of all newly diagnosed cancer cases and is responsible for 2.1% of all cancer-related deaths.
View Article and Find Full Text PDF